A Phase I Clinical Study to Evaluate The Safety and Pharmacokinetics of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
Latest Information Update: 25 Dec 2025
At a glance
- Drugs TQB 2922 (Primary)
- Indications Cancer; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 19 Dec 2025 Status changed from not yet recruiting to recruiting.
- 12 Dec 2025 New trial record